Abrotinib, as a selective inhibitor of Janus kinase 1 (JAK1), has been widely studied for the treatment of moderate to severe atopic dermatitis.
Abrocetinib was compared head to head with dabigatran in a phase III clinical study, and the results showed that in multiple efficacy measures, Abrocetinib was statistically superior.
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: